Latest California Healthline Stories
The Centers for Medicare & Medicaid Services launched this month the “What’s Covered” app, designed to provide yes-or-no answers about what services are covered under traditional Medicare. KHN took it for a test drive with real consumers.
Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss the latest national health spending estimates, another FDA crackdown on dietary supplements and lawsuits between insurers and the federal government that could result in a windfall for consumers.
Support for “Medicare-for-all” is becoming a front-runner topic among Democratic presidential candidates. But the phrase is being used to describe any number of policies.
The “Medicare–for-all” debate is already in full swing, but what does that phrase even mean? Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner for a beginner’s guide to the next big health policy debate. For “extra credit,” the panelists provide their favorite health policy stories of the week, and as a special Valentine’s Day bonus, their favorite #HealthPolicyValentines.
A new study examines how seniors with deteriorating strength and other physical functions deal with such challenges as taking a shower or getting dressed in the morning.
Congress and President Donald Trump are starting to wrestle with health policy issues, and health is already a key debate point in the early run-up to the 2020 Democratic presidential primaries. Might any major health policy legislation be passed and signed this year? Joanne Kenen of Politico, Anna Edney of Bloomberg News and Kimberly Leonard of The Washington Examiner, along with special guest Tom Miller of the American Enterprise Institute, join KHN’s Julie Rovner to discuss these issues and take questions from a live studio audience.
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.